Polycythemia Vera.

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Polycythemia vera (PV) is the most common myeloproliferative neoplasm (MPN), often linked to the JAK2 V1617F mutation.
• PV presents with erythrocytosis, leukocytosis, and thrombocytosis, frequently with splenomegaly, but can manifest with isolated findings.
• Distinguishing true erythrocytosis from pseudoerythrocytosis in PV is challenging due to concurrent plasma volume expansion.

Purpose of the Study:

• To clarify diagnostic challenges in Polycythemia vera (PV).
• To emphasize the importance of accurate red cell mass and plasma volume measurements for PV diagnosis.
• To highlight current management strategies and therapeutic considerations for PV patients.

Main Methods:

• Review of clinical presentations and diagnostic criteria for PV.
• Analysis of hematological parameters including hematocrit, hemoglobin, red cell mass, and plasma volume.
• Evaluation of diagnostic utility of JAK2 V617F mutation testing and bone marrow examination.

Main Results:

• Classical PV presentation includes erythrocytosis, leukocytosis, and thrombocytosis, but isolated findings can occur.
• Standard hematocrit measurements can be misleading in PV due to increased plasma volume.
• JAK2 V617F mutation testing and direct red cell mass/plasma volume measurements are crucial for accurate diagnosis, especially in cases of isolated thrombocytosis.

Conclusions:

• Accurate diagnosis of PV necessitates direct measurement of red cell mass and plasma volume, particularly when hematocrit is normal or misleading.
• Phlebotomy is the cornerstone of PV management, aiming for sex-specific normal hematocrit levels.
• While PV is indolent, effective therapies exist for managing symptoms and complications, avoiding treatments that increase leukemia risk.